# HMPL-306

Source: https://onco.cc/drugs/hmpl-306/  
OnCo record `hmpl-306` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

HMPL-306 is an experimental small-molecule drug from Hutchmed in phase 3 trials for acute myeloid leukaemia, aimed at IDH1 / IDH2.

## Summary

HMPL-306 is a small-molecule drug developed by Hutchmed. Its target is IDH1 / IDH2 (the sponsor names IDH1/IDH2 (mutant)). ClinicalTrials.gov describes the intervention as: Patients will receive HMPL-306 monotherapy: HMPL-306 PO at 250 mg QD (C1) + 150 mg QD (starting from C2), 28 days as a cycle. It is the investigational product in 1 recruiting or active industry-led phase 2 and phase 3 interventional cancer trial, including the phase 3 study NCT06387069 (A Study to Evaluate HMPL-306 in Patients With IDH1or IDH2-mutated Acute Myeloid Leukaemia), in acute myeloid leukaemia. The largest, NCT06387069, plans to enrol 316 participants with primary completion expected 2028-12-31. Status reflects the highest phase registered on ClinicalTrials.gov; no efficacy results are recorded here.

## Fields

- Kind: Treatment
- Status: phase-3
- Last checked: 2026-09-11
- Also known as: HMPL-306 Regimen
- Tags: pipeline; ctgov-ingest
- Modality: small molecule
- Mechanism: Small-molecule drug directed at IDH1 / IDH2, as stated in the ClinicalTrials.gov intervention record; the detailed mechanism is not stated.

## Sources

- ClinicalTrials.gov: trials of HMPL-306: https://clinicaltrials.gov/search?intr=HMPL-306

## Connected records

- cancers: [Acute myeloid leukaemia](https://onco.cc/cancers/aml/)
- targets: [IDH1 / IDH2](https://onco.cc/targets/idh/)
- companies: [Hutchmed](https://onco.cc/companies/hutchmed/)
- trials: [A Study to Evaluate HMPL-306 in Patients With IDH1or IDH2-mutated Acute Myeloid Leukemia](https://onco.cc/trials/nct06387069/)

---
JSON: https://onco.cc/api/v1/entities/hmpl-306.json